Insights

Gathering insights about Kineta…

Similar companies to Kineta

Kineta Tech Stack

Kineta uses 8 technology products and services including Cloudflare, Microsoft 365, particles.js, and more. Explore Kineta's tech stack below.

Cloudflare
Content Management System
Microsoft 365
Email
particles.js
Javascript Graphics
Underscore.js
Javascript Libraries
imagesLoaded
Javascript Libraries
HTML
Programming Languages
Bootstrap
UI Frameworks
Twitter
Widgets

Media & News

TuHURA Biosciences Completes Acquisition of Kineta
Acquisition adds Phase 2 ready novel VISTA inhibiting monoclonal antibody (mAb) to TuHURA's late-stage immuno-oncology pipeline TuHURA planning to initiate a Phase 2 randomized trial involving VISTA inhibiting antibody in 2nd Half 2025 Completion of the acquisition unlocks the fourth tranche of funds from $12.5 million aggregate PIPE financing announced June 3, 2025 TAMPA, Fla. , June 30, 2025 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA"), a Phase 3 immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, today announced the successful completion of the acquisition of Kineta, Inc. (OTCPK:KANT) ("Kineta"), the maker of the novel VISTA inhibiting mAb formerly known as KVA1213, now renamed as TBS-2025.
Jun 30, 2025 | www.prnewswire.com
TuHURA Biosciences, Inc. and Kineta, Inc. Stockholders Approve Proposed Merger and All Related Proposals
TAMPA, Fla. and SEATTLE , June 23, 2025 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, today announced with Kineta, Inc. (OTC Pink:KANT) ("Kineta"), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, that TuHURA stockholders approved all of the proposals set forth at the Company's Special Meeting of Stockholders held today, June 23, 2025 (the "TuHURA Special Meeting").
Jun 23, 2025 | www.prnewswire.com
TuHURA Biosciences and Kineta Present Updated Results from Kineta's Phase I-II Study of KVA12123 and TuHURA's Mechanism of IFx-Hu2.0 Responses After Anti-PD-1 Therapy Failure in Advanced Melanoma at the American Association for Cancer Research Annual Meeting
Kineta presents updated clinical data from VISTA-101 trial of KVA12123, demonstrating >90% VISTA receptor occupancy at 1,000mg dose level throughout the trial's every two weekly dosing interval (Q2W) TuHURA's Phase 3-ready IFx2.0 produced clinically meaningful anti-tumor responses and abscopal effect, after checkpoint inhibitor (CPI) therapy failure in patients with advanced melanoma when rechallenged with CPI TAMPA, Fla., April 28, 2025 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA"), a Phase 3 immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, today reported on poster presentations of Kineta Inc.'s ("Kineta") KVA12123 novel anti-VISTA antibody and TuHURA's IFx-Hu2.0 in advanced melanoma and at the American Association for Cancer Research (AACR) Annual Meeting in Chicago, IL.
Apr 28, 2025 | www.prnewswire.com
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of TuHURA Biosciences, Inc. - HURA
NEW YORK , Dec. 12, 2024 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm by ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating TuHURA Biosciences, Inc. (NASDAQ: HURA ), relating to the proposed merger with Kineta, Inc. Under the terms of the agreement, TuHURA would acquire the rights to Kineta's novel KVA12123 antibody for a combination of cash and shares of TuHURA common stock.
Dec 12, 2024 | www.prnewswire.com
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Kineta, Inc. - KANT
NEW YORK , Dec. 12, 2024 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm by ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Kineta, Inc. (OTC: KANT ), relating to the proposed merger with TuHURA Biosciences, Inc. Under the terms of the agreement, TuHURA would acquire the rights to Kineta's novel KVA12123 antibody for a combination of cash and shares of TuHURA common stock.
Dec 12, 2024 | www.prnewswire.com
TuHURA Biosciences, Inc. Enters into Definitive Merger Agreement to Acquire Kineta, Inc.
Opportunistic acquisition adds Phase 2 novel checkpoint inhibitor (KVA12123) to TuHURA's late stage pipeline Targeting Phase 2a/b trial with KVA12123 in mutated NPM1 AML in 2025 Cross product and technology synergies build on TuHURA's therapeutic focus on overcoming primary and acquired resistance to cancer immunotherapy Proposed Transaction expected to close in Q1 2025 TAMPA, FL AND SEATTLE, WA / ACCESSWIRE / December 12, 2024 / TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA"), a Phase 3 registration-stage immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, and Kineta, Inc. (OTC PINK:KANT) ("Kineta"), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, today announced that they have entered into a definitive merger agreement in which TuHURA would acquire Kineta, including the rights to Kineta's novel KVA12123 antibody, for a combination of cash and shares of TuHURA common stock via a merger transaction (the "Proposed Transaction"). "We are pleased to have entered into this definitive agreement with Kineta, which represents the culmination of the Exclusivity and Right of First Offer Agreement that TuHURA and Kineta entered into in July 2024.
Dec 12, 2024 | www.accesswire.com
Kineta Updates KVA12123 Clinical Results from Ongoing Phase 1/2 VISTA101 Study at Society for Immunotherapy of Cancer (2024)
Updated clinical data from VISTA101 presented at SITC 2024. Monotherapy arm fully enrolled and combination arm expected to be fully enrolled by year-end.
Nov 08, 2024 | www.globenewswire.com

Kineta's Email Address Formats

Kineta uses at least 2 format(s):

Kineta Email Formats	Example	Percentage
FLast@kineta.us	JDoe@kineta.us	90%
First@kineta.us	John@kineta.us	5%
LFirst@kineta.us	DJohn@kineta.us	5%
FLast@kinetabio.com	JDoe@kinetabio.com	94%
First@kinetabio.com	John@kinetabio.com	4%
FirstLast@kinetabio.com	JohnDoe@kinetabio.com	2%

Frequently Asked Questions

Where is Kineta's headquarters located?

Kineta's main headquarters is located at Seattle, Washington United States. The company has employees across 3 continents, including North AmericaAsiaSouth America.

What is Kineta's phone number?

You can contact Kineta's main corporate office by phone at

+1-206-378-****

. For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is Kineta's stock symbol?

Kineta is a publicly traded company; the company's stock symbol is KA.

What is Kineta's official website and social media links?

Kineta's official website is kinetabio.com and has social profiles on LinkedIn.

What is Kineta's SIC code NAICS code?

Kineta's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Kineta have currently?

As of June 2026, Kineta has approximately 30 employees across 3 continents, including North AmericaAsiaSouth America. Key team members include Vice President Of Business Development: B. J.President And Chief Operating Officer: R. H.Senior Vice President, Translational Development: E. T.. Explore Kineta's employee directory with LeadIQ.

What industry does Kineta belong to?

Kineta operates in the Biotechnology Research industry.

What technology does Kineta use?

Kineta's tech stack includes CloudflareMicrosoft 365particles.jsUnderscore.jsimagesLoadedHTMLBootstrapTwitter.

What is Kineta's email format?

Kineta's email format typically follows the pattern of FLast@kineta.us. Find more Kineta email formats with LeadIQ.

When was Kineta founded?

Kineta was founded in 2008.

Kineta

Q: What is Kineta's official website and social media links?

Kineta's official website is kinetabio.com. Kineta has social profiles on LinkedIn.

Q: How many employees does Kineta have currently?

Kineta has approximately 30 employees.

Q: What technology does Kineta use?

Kineta's tech stack includes jQuery, Microsoft 365, yepnope.js, Yoast SEO, RSS.

Q: What is Kineta's NAICS code?

Kineta's NAICS code is 541714 (Research and Development in Biotechnology (except Nanobiotechnology)).

Biotechnology ResearchWashington, United States11-50 Employees

Kineta is a clinical stage biotechnology company with a mission to develop next-generation immunotherapies that transform patients’ lives.

Company Overview

Headquarters: Seattle, Washington United States
Phone number: +1-206-378-****
Website: kinetabio.com
SIC Code: 8733 - Noncommercial Research Organizations
Stock Symbol: KA
NAICS Code: 541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded: 2008
Employees: 11-50

Media & News

Funding & Financials

$10M$25M
Kineta's revenue is estimated to be in the range of $10M$25M

Funding & Financials

$10M$25M
Kineta's revenue is estimated to be in the range of $10M$25M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

Insights

Similar companies to Kineta

Anavex Life Sciences

Affimed

Aligos Therapeutics

Annexon Biosciences

AN2 Therapeutics

Amgen

Applied Molecular Transport

Alterity Therapeutics

Ambys Medicines

Kineta Tech Stack

Media & News

TuHURA Biosciences Completes Acquisition of Kineta

TuHURA Biosciences, Inc. and Kineta, Inc. Stockholders Approve Proposed Merger and All Related Proposals

TuHURA Biosciences and Kineta Present Updated Results from Kineta's Phase I-II Study of KVA12123 and TuHURA's Mechanism of IFx-Hu2.0 Responses After Anti-PD-1 Therapy Failure in Advanced Melanoma at the American Association for Cancer Research Annual Meeting

SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of TuHURA Biosciences, Inc. - HURA

SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Kineta, Inc. - KANT

TuHURA Biosciences, Inc. Enters into Definitive Merger Agreement to Acquire Kineta, Inc.

Kineta Updates KVA12123 Clinical Results from Ongoing Phase 1/2 VISTA101 Study at Society for Immunotherapy of Cancer (2024)

Kineta's Email Address Formats

Frequently Asked Questions

Where is Kineta's headquarters located?

What is Kineta's phone number?

What is Kineta's stock symbol?

What is Kineta's official website and social media links?

What is Kineta's SIC code NAICS code?

How many employees does Kineta have currently?

What industry does Kineta belong to?

What technology does Kineta use?

What is Kineta's email format?

When was Kineta founded?

Kineta

Company Overview

Media & News

TuHURA Biosciences Completes Acquisition of Kineta

TuHURA Biosciences, Inc. and Kineta, Inc. Stockholders Approve Proposed Merger and All Related Proposals

TuHURA Biosciences and Kineta Present Updated Results from Kineta's Phase I-II Study of KVA12123 and TuHURA's Mechanism of IFx-Hu2.0 Responses After Anti-PD-1 Therapy Failure in Advanced Melanoma at the American Association for Cancer Research Annual Meeting

Funding & Financials

Funding & Financials

Company Leadership

Employee Directory

Ready to create more pipeline?

Ready to create more pipeline?